Figure 4
From: DCZ19931, a novel multi-targeting kinase inhibitor, inhibits ocular neovascularization
DCZ19931 exhibits anti-angiogenic effects in vitro. (A) HUVECs were pre-treated with VEGF (10 ng/mL) for 12 h and then treated with DCZ19931 at the concentration of 10 nM to 1 μM for 24 h. Cell viability was determined by MTT assay (n = 4). (B–D) HUVECs were pre-treated with VEGF (10 ng/mL) for 12 h and then treated with DCZ19931 (500 nM), Ranibizumab (250 μg/mL), DCZ19931 (500 nM) plus Ranibizumab (250 μg/mL), or left untreated (VEGF) for 24 h. The group without VEGF treatment was taken as Ctrl group. Cell proliferation was detected by EdU assays (B, n = 4, scale bar, 20 μm). The cells were allowed to migrate for 12 h at 37 °C and 5% CO2 and cell migration ability was assessed by transwell assays (C, n = 4, scale bar, 20 μm). HUVECs were seeded on matrigel matrix and cultured. Tube formation ability was observed under a light microscope at 8 h after seeding (D, n = 4, scale bar, 100 μm). (E) The mouse choroidal sprouting assays were conducted to measure the angiogenic potency of choroidal explants at day 4, day 5, and day 6 after culture. Representative images of the choroidal sprouting areas at indicated time points were shown (n = 4, scale bar, 200 µm). Statistical significance was evaluated by one-way ANOVA followed by Bonferroni post hoc test. For (A–D): *P < 0.05 indicated significant difference between the marked groups. For (E): *P < 0.05 vs. VEGF group, #P < 0.05 vs. DCZ19931 + Ranibizumab group.
